Page 4 - Clinical Hospital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa

Baylor college of medicineUnited statesSantiago de compostelaCastilla la manachaComunidad autonoma de catalunaBaja californiaComunidad autonoma de extremaduraUniversity hospitalJerez de la fronteraSanta cruz de tenerifeSan sebastianPais vascoCruz merinoLaguna tenerifeJuan alicanteSnehal patel